Health Boards
Sun-01-05-2016, 19:31 PM
Hello All;
I continue to have great success with the use of Fumaderm for my Psoriasis, lesions now non-existent for several years. I have now reduced my maintenance dose to 1 x 120 mg every third day. However, I need to throw out a word of caution regarding Fumaderm.
The European Medicines Agency (EMA) has issued new advice for doctors and patients in order to minimise the risk of progressive multifocal leukoencephalopathy (PML) in patients treated with the multiple sclerosis medicine Tecfidera (dimethyl fumarate).
Some patients who are being treated with the psoriasis medicine Fumaderm, whose active substances include dimethyl fumarate, the active substance in Tecfidera, may also have persistently low levels of lymphocytes, and so may also be at higher risk of PML if they have been infected with JC virus. Therefore, related recommendations regarding the monitoring of white blood cell levels are being issued for these medicines, based on the evidence available from the case reports of PML received for Fumaderm.
Further information is available at LINK REMOVED
William Mateychuk
I continue to have great success with the use of Fumaderm for my Psoriasis, lesions now non-existent for several years. I have now reduced my maintenance dose to 1 x 120 mg every third day. However, I need to throw out a word of caution regarding Fumaderm.
The European Medicines Agency (EMA) has issued new advice for doctors and patients in order to minimise the risk of progressive multifocal leukoencephalopathy (PML) in patients treated with the multiple sclerosis medicine Tecfidera (dimethyl fumarate).
Some patients who are being treated with the psoriasis medicine Fumaderm, whose active substances include dimethyl fumarate, the active substance in Tecfidera, may also have persistently low levels of lymphocytes, and so may also be at higher risk of PML if they have been infected with JC virus. Therefore, related recommendations regarding the monitoring of white blood cell levels are being issued for these medicines, based on the evidence available from the case reports of PML received for Fumaderm.
Further information is available at LINK REMOVED
William Mateychuk